Lotus Ventures Inc. (CSE:J, FRA:LV9, OTC:LTTSF) (the “Company” or “Lotus”) has completed its third harvest and has completed the processing of crop #1. Initial production volume, yields, lab tests, and plant health are all positive. The company is finalizing its first shipment to its streaming partner Auxly Cannabis Group Inc. After Lotus completes the processing and testing of a number of crops, the Company will provide guidance on production targets and financial expectations.

CFO Appointment
Lotus continues to expand its team strategically and would like to welcome Mr. Gavin Dew as Chief Financial Officer. Mr. Dew brings a wealth of experience in business across Canada, holding an MBA from the University of Oxford, and a BA from the University of British Columbia. Gavin has worked for large firms including the pipeline and gaming industry. He has also worked on numerous start-up firms in the services and tech sectors.


Mr. Dew is highly involved in the Vancouver community, with past and present positions including the board of the Business Council of BC, government appointee to the Board of Kwantlen Polytechnic University, UBC Senate, and the Policy Council of the Greater Vancouver Board of Trade.

Grant of Options
In October, 975,000 incentive options at 20 cents were exercised by directors and qualified consultants. The Company has granted 975,000 stock options to eligible persons at an exercise price of 20 cents per share for 10 years.

On Behalf of the Board:
Lotus Ventures Inc.
“Dale McClanaghan”
Dale McClanaghan, President and CEO

About Lotus Ventures Inc.
Lotus Ventures Inc. (CSE: J) is an Okanagan-based licensed producer focused on growing exceptional cannabis products for the wholesale and recreational market in Canada. Lotus operates an innovative 22,500 square foot indoor facility with unique proven strains and an entirely handcrafted production process created by one of the region’s most experienced growing teams.

Lotus designed its facility with a perpetual production cycle harvesting one of six production rooms every two weeks. The facility was designed to consistently produce high-end cannabis at low production costs, and the Company is focused on being cash flow positive in the year 2020.

Earlier this year, Lotus Ventures launched its initial consumer-focused brand “Lotus Cannabis Co.” targeting discerning consumers. The Company is in the process of obtaining a Processing licence, which when issued, permits the sale of cannabis to provincial distributors and retail supply chains.

For Further Information:
Dale McClanaghan
President & CEO
dalemcclanaghan@gmail.com
604-644-9844

Daniel McRobert
Investor Relations
investors@lotuscannabis.ca
604-842-4625

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Click here to connect with Lotus Ventures Inc (CSE:J) for an Investor Presentation.

Source

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less